(Nasdaq: GNPX) Profile
OUR NEW PROFILE IS: (NASDAQ: GNPX) _____________________________________________________________ GNPX HAS ALREADY RECEIVED FAST TRACK DESIGNATION FOR ACCLAIM 2 GENPREX RECEIVES SAFETY REVIEW COMMITTEE APPROVAL TO ADVANCE TO PHASE 2 EXPANSION PORTION OF ACCLAIM-1 CLINICAL TRIAL OF REQORSA® IN COMBINATION WITH TAGRISSO® IN ADVANCED NON-SMALL CELL LUNG CANCER INDEPENDENT RESEARCHERS FIND THAT TUSC2, THE GENE DELIVERED […]
(Nasdaq: TRNR) Profile
OUR NEW PROFILE IS: (NASDAQ: TRNR) _________________________________________________________________________________________ (TRNR) INTERACTIVE STRENGTH INC. D/B/A FORME ANNOUNCES CLOSING OF $12 MILLION INITIAL PUBLIC OFFERING INTERACTIVE STRENGTH INC. AND AETHOS PARTNER TO BRING CUTTING EDGE FORME TRAINING TECHNOLOGY INTO HOTELS CHECK OUT THE INVESTOR PRESENTATION HERE _______________________________ Hello Everyone, We have a profile back in our cross hairs that we took […]
(Nasdaq: NCPL) Profile
OUR NEW PROFILE IS: (NASDAQ: NCPL) REVENUE GROWTH OF 48% YEAR-OVER-YEAR TO $5.4 MILLION IN THE FIRST 9 MONTHS OF 2023 OVER THE PAST NINE MONTHS NETCAPITAL HAS GENERATED SUBSTANTIAL REVENUE GROWTH WHILE GENERATING POSITIVE OPERATING AND NET INCOME THE COMPANY BOASTS MORE THAN 100,000 USERS ALREADY WITH OVER $5O MILLION RAISED SO FAR THIS ONE […]
(Nasdaq: PRPH) Profile
OUR NEW PROFILE IS: (NASDAQ: PRPH) 2022 REVENUES TOTALED $122 MILLION AS OF DEC. 31, CASH AND EQUIVALENTS TOTALED $17.4 MILLION WITH WORKING CAPITAL OF $44.8 MILLION PRPH WILL RELEASE FIRST QUARTER FINANCIAL RESULTS ON THURSDAY PROPHASE LABS CEO TED KARKUS NAMED ONE OF INC MAGAZINE’S 10 MOST INNOVATIVE HEALTHCARE LEADERS TO WATCH IN 2023 […]
(Nasdaq: TRNR) Profile
OUR NEW PROFILE IS: (NASDAQ: TRNR) ___________________________________ (TRNR) INTERACTIVE STRENGTH INC. D/B/A FORME ANNOUNCES CLOSING OF $12 MILLION INITIAL PUBLIC OFFERING HOME FITNESS MARKET WAS 11.3BILL IN 2021 & WILL ATTAIN USD 17.3 BILLION BY 2030 GROWING AT 4.9% CAGR – ACUMEN RESEARCH AND CONSULTING CHECK OUT THE INVESTOR PRESENTATION HERE_ _______________________________ ______________________________ Hello Everyone, We have a […]
(Nasdaq: NMTC) Profile
OUR NEW PROFILE IS: (NASDAQ: NMTC) STRATEGIC PARTNERSHIP WITH ZIMMER BIOMET (NYSE:ZBH, ~$27B MKT CAP) TO EXCLUSIVELY COMMERCIALIZE AND DISTRIBUTE EVO® DIAGNOSTIC ELECTRODES; ACCELERATED PAYMENT OF $3.5 MILLION RECEIVED IN AUGUST 2022 NEURONE® RECEIVES FDA 510(K) CLEARANCE TO MARKET ITS EVO® SEEG SYSTEM FOR LESS THAN 30 DAY USE NEUROONE® SUCCESSFULLY COMPLETES INITIAL ANIMAL IMPLANT […]
BRAND NEW NASDAQ: VUZI ON WATCH!
OUR NEW PROFILE IS: (NASDAQ: VUZI) __________ VUZIX IS A PIONEER IN WEARABLE COMPUTING, AUGMENTED REALITY, OPTICS AND DISPLAY ENGINES AND HAS BEEN DELIVERING SOLUTIONS TO CUSTOMERS FOR OVER 20 YEARS VUZI IS SITTING WITH JUST OVER $73 MILLION IN CASH AS OF DECEMBER 31 VUZIX ACHIEVES RECORD SMART GLASSES SALES IN Q1 2023 FOR […]
CTXR BRAND NEW PROFILE!
OUR NEW PROFILE IS: NASDAQ: CTXR “MINO-WRAP” COULD REVOLUTIONIZE $400 MILLION POST-MASTECTOMY INFECTION PREVENTION MARKET $41.7 MILLION IN CASH AND CASH EQUIVALENTS AS OF SEPTEMBER 30, 2022 MINO-LOK® PHASE 3 TRIAL CLOSER TO COMPLETION WITH 169 PATIENTS RECRUITED, 72 FAILURE EVENTS AND 17 PATIENTS IN ACTIVE TREATMENT OR PENDING DATA REVIEW DOWNLOAD THE INVESTOR […]
(NASDAQ: GNPX) Brand NEW Profile
OUR NEW PROFILE IS: (NASDAQ: GNPX) ________________________ GNPX HAS ALREADY RECEIVED FAST TRACK DESIGNATION FOR ACCLAIM 2 GENPREX ANNOUNCES U.S. PATENT FOR REQORSA™ IMMUNOGENE THERAPY IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS TO TREAT CANCERS INDEPENDENT RESEARCHERS FIND THAT TUSC2, THE GENE DELIVERED BY GENPREX’S REQORSA®, FUNCTIONS AS A NOVEL TUMOR SUPPRESSOR FOR GLIOBLASTOMA GENPREX […]
(Nasdaq: BTCY) Profile
OUR NEW PROFILE IS: (NASDAQ: BTCY) ___________________________________ Revenue is up 27.4% YOY Residual revenues are driven by a 95% retention rate Biotricity surpasses $10 million in annual revenue run rate Bioheart named to TIME’s list of The Best Inventions of 2022′ Biotricity surpasses 2 billion recorded and analyzed heartbeats for atrial […]